Performance of rapid diagnostic tests for the detection of anti-HBs in various patient populations

Hepatitis B virus (HBV) infection is a major cause of chronic liver disease that affects approximately 240 million people worldwide [1]. Each year, nearly 700,000 people die from HBV-related chronic liver disease through end-stage cirrhosis, liver failure or hepatocellular carcinoma [2]. Despite the availability of an effective vaccine against HBV and of potent and safe antiviral drugs, chronic hepatitis B remains a global health problem with its prevalence varying geographically. The World Health Organization (WHO) recommended that the first vaccine dose be administered in all infants as early as possible after birth.
Source: Journal of Clinical Virology - Category: Virology Authors: Tags: Short communication Source Type: research